CLYM - NASDAQ

Climb Bio, Inc.

CLYM·NASDAQ

$10.98

-2.0%

HealthcareBiotechnology

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$748.75M

EPS-0.8800

P/E Ratio-12.48

Earnings Date08/11/2026

clym

Net Interest Income

Last Annual Value

8.32M

3-Year CAGR

82%

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Climb Bio, Inc. Competitors Analysis of Net Interest Income

CLYM · NASDAQ

Company	Net Interest Income	CAGR 3Y	CAGR 5Y	CAGR 10Y
Climb Bio, Inc. NASDAQ:CLYM	8.32M	21.7%	N/A	N/A
Inovio Pharmaceuticals, Inc. NASDAQ:INO	2.42M	-29.5%	11.1%	6.8%
Spero Therapeutics, Inc. NASDAQ:SPRO	2.51M	-13.9%	N/A	N/A
Turn Therapeutics Inc. NASDAQ:TTRX	29.58K	23.0%	N/A	N/A
Agenus Inc. NASDAQ:AGEN	-55.27M	N/A	N/A	N/A
Anixa Biosciences, Inc. NASDAQ:ANIX	673.00K	-14.6%	220.2%	N/A
Seres Therapeutics, Inc. NASDAQ:MCRB	2.23M	N/A	N/A	5.9%
Cognition Therapeutics, Inc. NASDAQ:CGTX	-13.00K	N/A	N/A	N/A
Context Therapeutics Inc. NASDAQ:CNTX	3.38M	42.6%	N/A	N/A
TuHURA Biosciences, Inc. NASDAQ:HURA	-489.05K	N/A	N/A	N/A
Inhibikase Therapeutics, Inc. NASDAQ:IKT	3.72M	51.9%	N/A	N/A

Climb Bio, Inc. Fair Value Envelope

CLYM · NASDAQ

Our analysis suggests that CLYM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $10.9813, this represents a potential HIDDEN relative to our calculated worth for Climb Bio, Inc..

HIDDEN

Intrinsic Value

Current Price: $10.9813

Related Guides

Blog Categories

Continue your CLYM research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.